Aethlon Medical Free Cash Flow (FCF) History (AEMD)
Aethlon Medical reported −$7.0M in free cash flow for fiscal 2026, an increase of $643,436 from the previous fiscal year.
View full Aethlon Medical company overviewAethlon Medical free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2026 | 2026-03-31 | −$7.0M | $643,436 | — | — |
| 2025 | 2025-03-31 | −$7.6M | $2.7M | — | — |
| 2024 | 2024-03-31 | −$10.4M | $1.1M | — | — |
| 2023 | 2023-03-31 | −$11.4M | −$1.3M | — | −1993.62% |
| 2022 | 2022-03-31 | −$10.1M | −$3.3M | — | −3439.01% |
| 2021 | 2021-03-31 | −$6.8M | −$1.5M | — | −1035.47% |
| 2020 | 2020-03-31 | −$5.3M | −$1.1M | — | −822.73% |
| 2019 | 2019-03-31 | −$4.3M | −$357,930 | — | −1869.76% |
| 2018 | 2018-03-31 | −$3.9M | −$413,170 | — | −2630.24% |
| 2017 | 2017-03-31 | −$3.5M | $816,281 | — | −898.39% |
| 2016 | 2016-03-31 | −$4.3M | $710,800 | — | −489.37% |
| 2015 | 2015-03-31 | −$5.0M | −$2.8M | — | −662.29% |
| 2014 | 2014-03-31 | −$2.2M | −$136,170 | — | −137.64% |
| 2013 | 2013-03-31 | −$2.1M | −$255,767 | — | −170.64% |
| 2012 | 2012-03-31 | −$1.8M | $127,784 | — | −135.56% |
| 2011 | 2011-03-31 | −$2.0M | — | — | — |
Aethlon Medical quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$1.9M | $308,869 | — | — |
| Q1 2026 | 2025-06-30 | −$1.7M | $32,600 | — | — |
| Q4 2025 | 2025-03-31 | −$1.7M | $895,508 | — | — |
| Q3 2025 | 2024-12-31 | −$2.0M | $373,662 | — | — |
| Q2 2025 | 2024-09-30 | −$2.2M | $496,358 | — | — |
| Q1 2025 | 2024-06-30 | −$1.7M | $965,233 | — | — |
| Q4 2024 | 2024-03-31 | −$2.6M | $387,656 | — | — |
| Q3 2024 | 2023-12-31 | −$2.4M | −$284,042 | — | — |
| Q2 2024 | 2023-09-30 | −$2.7M | $906,630 | — | — |
| Q1 2024 | 2023-06-30 | −$2.7M | $57,316 | — | — |
| Q4 2023 | 2023-03-31 | −$3.0M | $353,471 | — | −515.11% |
| Q3 2023 | 2022-12-31 | −$2.1M | $673,452 | — | — |
| Q2 2023 | 2022-09-30 | −$3.6M | −$1.7M | — | — |
| Q1 2023 | 2022-06-30 | −$2.8M | −$659,884 | — | — |
| Q4 2022 | 2022-03-31 | −$3.3M | −$1.1M | — | −25247.61% |
| Q3 2022 | 2021-12-31 | −$2.8M | −$547,151 | — | −16218.10% |
| Q2 2022 | 2021-09-30 | −$1.9M | −$686,364 | — | −1453.87% |
| Q1 2022 | 2021-06-30 | −$2.1M | −$990,420 | — | −1599.05% |
| Q4 2021 | 2021-03-31 | −$2.2M | −$619,926 | — | −6554.73% |
| Q3 2021 | 2020-12-31 | −$2.2M | −$944,431 | — | −356.70% |
| Q2 2021 | 2020-09-30 | −$1.2M | −$39,980 | — | — |
| Q1 2021 | 2020-06-30 | −$1.1M | $128,789 | — | — |
| Q4 2020 | 2020-03-31 | −$1.6M | −$226,483 | — | −785.55% |
| Q3 2020 | 2019-12-31 | −$1.3M | −$198,206 | — | −310.67% |
| Q2 2020 | 2019-09-30 | −$1.2M | −$201,011 | — | — |
| Q1 2020 | 2019-06-30 | −$1.2M | −$430,140 | — | −4161.90% |
| Q4 2019 | 2019-03-31 | −$1.4M | −$378,426 | — | −1746.84% |
| Q3 2019 | 2018-12-31 | −$1.1M | −$296,590 | — | — |
| Q2 2019 | 2018-09-30 | −$991,265 | $37,248 | — | — |
| Q1 2019 | 2018-06-30 | −$818,431 | $279,838 | — | −546.99% |
| Q4 2018 | 2018-03-31 | −$1.0M | −$51,609 | — | −1362.14% |
| Q3 2018 | 2017-12-31 | −$789,674 | −$1,433 | — | −1055.53% |
| Q2 2018 | 2017-09-30 | −$1.0M | −$91,337 | — | — |
| Q1 2018 | 2017-06-30 | −$1.1M | −$268,791 | — | — |
| Q4 2017 | 2017-03-31 | −$967,438 | $159,722 | — | — |
| Q3 2017 | 2016-12-31 | −$788,241 | $184,985 | — | — |
| Q2 2017 | 2016-09-30 | −$937,176 | $503,046 | — | −241.89% |
| Q1 2017 | 2016-06-30 | −$829,478 | −$31,472 | — | −17895.97% |
| Q4 2016 | 2016-03-31 | −$1.1M | $770,477 | — | — |
| Q3 2016 | 2015-12-31 | −$973,226 | $784,185 | — | — |
| Q2 2016 | 2015-09-30 | −$1.4M | −$809,605 | — | — |
| Q1 2016 | 2015-06-30 | −$798,006 | −$34,257 | — | — |
| Q4 2015 | 2015-03-31 | −$1.9M | −$996,792 | — | −955.45% |
| Q3 2015 | 2014-12-31 | −$1.8M | −$1.1M | — | −5256.36% |
| Q2 2015 | 2014-09-30 | −$630,617 | $109,652 | — | −131.63% |
| Q1 2015 | 2014-06-30 | −$763,749 | −$698,709 | — | −1488.91% |
| Q3 2014 | 2013-12-31 | −$900,845 | −$405,351 | — | −1180.46% |
| Q3 2013 | 2012-12-31 | −$661,777 | −$119,490 | — | −316.97% |
| Q4 2012 | 2012-03-31 | −$740,269 | −$284,900 | — | — |
| Q3 2012 | 2011-12-31 | −$65,040 | $486,341 | — | −6.79% |
| Q2 2012 | 2011-09-30 | −$495,494 | $105,673 | — | — |
| Q1 2012 | 2011-06-30 | −$542,287 | −$179,330 | — | — |
| Q4 2011 | 2011-03-31 | −$455,369 | — | — | — |
| Q3 2011 | 2010-12-31 | −$551,381 | — | — | — |
| Q2 2011 | 2010-09-30 | −$601,167 | — | — | — |
| Q1 2011 | 2010-06-30 | −$362,957 | — | — | — |
Aethlon Medical free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$6.8M to −$7.0M, a net decrease of $177,275. Aethlon Medical's latest reported quarter, Q1 2027, generated −$1.9M in free cash flow, an increase of $308,869 year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Aethlon Medical filings at SEC.gov ↗